BRPI0614529A8 - polipeptídeo isolado, composição farmacêutica, método para proteger, manter ou melhorar a viabilidade de uma célula, tecido ou órgão responsivos isolados do corpo do mamífero, uso de um polipeptídeo isolado, método para facilitar a transcitose de uma molécula, ácido nucleico isolado, vetor, célula hospedeira, e, método para produzir recombinantemente o polipeptídeo isolado - Google Patents
polipeptídeo isolado, composição farmacêutica, método para proteger, manter ou melhorar a viabilidade de uma célula, tecido ou órgão responsivos isolados do corpo do mamífero, uso de um polipeptídeo isolado, método para facilitar a transcitose de uma molécula, ácido nucleico isolado, vetor, célula hospedeira, e, método para produzir recombinantemente o polipeptídeo isoladoInfo
- Publication number
- BRPI0614529A8 BRPI0614529A8 BRPI0614529A BRPI0614529A BRPI0614529A8 BR PI0614529 A8 BRPI0614529 A8 BR PI0614529A8 BR PI0614529 A BRPI0614529 A BR PI0614529A BR PI0614529 A BRPI0614529 A BR PI0614529A BR PI0614529 A8 BRPI0614529 A8 BR PI0614529A8
- Authority
- BR
- Brazil
- Prior art keywords
- isolated
- tissue
- isolated polypeptide
- peptides
- tissue protective
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 15
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 14
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 230000002708 enhancing effect Effects 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 210000000056 organ Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000031998 transcytosis Effects 0.000 title abstract 2
- 230000035899 viability Effects 0.000 title abstract 2
- 230000002669 organ and tissue protective effect Effects 0.000 abstract 8
- 239000003446 ligand Substances 0.000 abstract 7
- 102000005962 receptors Human genes 0.000 abstract 7
- 108020003175 receptors Proteins 0.000 abstract 7
- 108091035707 Consensus sequence Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 102000003675 cytokine receptors Human genes 0.000 abstract 2
- 108010057085 cytokine receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000710 homodimer Substances 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70574105P | 2005-08-05 | 2005-08-05 | |
| US60/705741 | 2005-08-05 | ||
| US70627605P | 2005-08-08 | 2005-08-08 | |
| US60/706276 | 2005-08-08 | ||
| US83173706P | 2006-07-18 | 2006-07-18 | |
| US60/831737 | 2006-07-18 | ||
| PCT/US2006/031061 WO2007019545A2 (en) | 2005-08-05 | 2006-08-07 | Tissue protective peptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0614529A2 BRPI0614529A2 (pt) | 2011-08-09 |
| BRPI0614529A8 true BRPI0614529A8 (pt) | 2016-07-12 |
Family
ID=37728020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0614529A BRPI0614529A8 (pt) | 2005-08-05 | 2006-08-07 | polipeptídeo isolado, composição farmacêutica, método para proteger, manter ou melhorar a viabilidade de uma célula, tecido ou órgão responsivos isolados do corpo do mamífero, uso de um polipeptídeo isolado, método para facilitar a transcitose de uma molécula, ácido nucleico isolado, vetor, célula hospedeira, e, método para produzir recombinantemente o polipeptídeo isolado |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8071554B2 (enExample) |
| EP (5) | EP2594279B1 (enExample) |
| JP (6) | JP5274253B2 (enExample) |
| KR (7) | KR20180067735A (enExample) |
| CN (2) | CN101378772B (enExample) |
| AU (1) | AU2006278264B2 (enExample) |
| BR (1) | BRPI0614529A8 (enExample) |
| CA (3) | CA2982909A1 (enExample) |
| DK (3) | DK2540309T3 (enExample) |
| EA (1) | EA015672B1 (enExample) |
| ES (3) | ES2653790T3 (enExample) |
| HU (3) | HUE035793T2 (enExample) |
| IL (3) | IL189287A (enExample) |
| IN (1) | IN2014CN02050A (enExample) |
| LT (2) | LT2594279T (enExample) |
| MX (3) | MX364100B (enExample) |
| NO (1) | NO20081112L (enExample) |
| NZ (1) | NZ565937A (enExample) |
| PL (3) | PL2371855T3 (enExample) |
| PT (3) | PT2540309T (enExample) |
| SG (2) | SG10201805825SA (enExample) |
| SI (3) | SI2594279T1 (enExample) |
| UA (1) | UA100222C2 (enExample) |
| WO (1) | WO2007019545A2 (enExample) |
| ZA (1) | ZA201101890B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US9345745B2 (en) * | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| US9585932B2 (en) * | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| CN101378772B (zh) | 2005-08-05 | 2013-12-04 | 阿拉伊姆药品公司 | 组织保护性肽及其用途 |
| WO2007142288A1 (ja) * | 2006-06-07 | 2007-12-13 | The University Of Tokushima | エリスロポエチンを用いた虚血性疾患の治療 |
| DK2081956T3 (da) | 2006-11-13 | 2013-06-24 | Charite Universitaetsmedizin | FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT |
| PL2245056T4 (pl) * | 2008-01-22 | 2016-01-29 | Araim Pharmaceuticals Inc | Peptydy i analogi peptydowe chroniące tkanki do zapobiegania i leczenia chorób i schorzeń związanych z uszkodzeniem tkanek |
| AU2016203452B2 (en) * | 2008-01-22 | 2018-02-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| AU2014203195B2 (en) * | 2008-01-22 | 2016-03-31 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| US9566349B2 (en) * | 2010-10-14 | 2017-02-14 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| US8791234B2 (en) * | 2010-10-14 | 2014-07-29 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| CN102180948A (zh) * | 2011-03-03 | 2011-09-14 | 复旦大学附属中山医院 | 一种具有肾脏保护作用的短肽及其制备方法和应用 |
| CN102212111B (zh) * | 2011-05-05 | 2014-04-30 | 中国人民解放军第三军医大学 | 小分子多肽和小分子多肽脂质体及其运用 |
| US20140178335A1 (en) * | 2011-07-27 | 2014-06-26 | Neumedicines, Inc. | Use of il-12 to generate endogenous erythropoietin |
| WO2013042118A1 (en) * | 2011-09-20 | 2013-03-28 | A.A. Cash Technology Ltd | Methods and devices for occluding blood flow to an organ |
| KR101148191B1 (ko) * | 2011-09-27 | 2012-05-23 | 김후정 | 에리스로포이에틴-유래 펩타이드 및 그 용도 |
| WO2013158871A1 (en) * | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
| MX2016000448A (es) * | 2013-07-17 | 2016-05-12 | Araim Pharmaceuticals Inc | Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido. |
| CN104744593A (zh) * | 2013-12-25 | 2015-07-01 | 深圳先进技术研究院 | 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用 |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| KR20150130616A (ko) * | 2014-05-13 | 2015-11-24 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| CN105906690A (zh) * | 2014-06-22 | 2016-08-31 | 马恒标 | 组织保护活性多肽sl9及其应用 |
| MX391259B (es) * | 2015-10-14 | 2025-03-21 | X Therma Inc | Composiciones y métodos para reducir la formación de cristales de hielo. |
| WO2017189988A1 (en) | 2016-04-29 | 2017-11-02 | Araim Pharmaceuticals, Inc. | Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage |
| AU2017357374B2 (en) * | 2016-11-10 | 2023-05-18 | Asc Regenity Ltd. | Cosmetic formulations for topical applications containing erythropoietin-derived molecules |
| WO2018155997A1 (ko) * | 2017-02-27 | 2018-08-30 | 재단법인 대구경북과학기술원 | 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용 |
| CN108503690B (zh) * | 2017-02-28 | 2020-07-03 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
| US11260101B2 (en) | 2017-02-28 | 2022-03-01 | Jinan University | Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof |
| WO2019199661A1 (en) * | 2018-04-08 | 2019-10-17 | Brim Biotechnology, Inc. | Application of pedf-derived short peptides in tendon healing |
| KR102300060B1 (ko) | 2018-06-12 | 2021-09-08 | 주식회사 엘지에너지솔루션 | 2열 터미널 구조의 pcb 다이렉트 커넥터 |
| AU2019337564A1 (en) | 2018-09-10 | 2021-05-06 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
| CN112390877B (zh) * | 2019-08-16 | 2022-10-04 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
| CN118255845B (zh) * | 2022-12-27 | 2025-07-11 | 上海瑞吉康生物医药有限公司 | 相分离逆转多肽的变体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| US4558006A (en) * | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
| DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US6063625A (en) * | 1993-02-12 | 2000-05-16 | Board Of Trustees Of Leland S, Stanford, Jr. University | Regulated transcription of targeted genes and other biological events |
| US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
| US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| WO1995021919A2 (en) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| EP0886648B8 (en) * | 1995-06-07 | 2004-03-03 | Ortho Pharmaceutical Corporation | Compounds and peptides that bind to the erythropoietin receptor |
| AU4267297A (en) * | 1997-09-11 | 1998-09-22 | Regents Of The University Of California, The | Method of alleviating neuropathic pain |
| US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| CZ20013695A3 (cs) * | 1999-04-13 | 2002-02-13 | Kenneth S. Warren Laboratories | Farmaceutický prostředek |
| AU2001252650A1 (en) * | 2000-04-28 | 2001-11-12 | Effector Cell Institute | Novel derivative of cell chemotactic factor |
| MXPA03005406A (es) * | 2000-12-20 | 2003-09-25 | Hoffmann La Roche | Conjugados de eritropoyetina. |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| HUP0400703A3 (en) | 2001-02-06 | 2006-06-28 | Merck Patent Gmbh | Modified erythropoietin (epo) with reduced immunogenicity |
| IL158261A0 (en) * | 2001-04-04 | 2004-05-12 | Genodyssee | New polynucleotides and polypeptides of the erythropoietin gene |
| KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| NZ537306A (en) | 2002-07-01 | 2008-11-28 | Kenneth S Warren Inst Inc | Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier |
| KR100478455B1 (ko) | 2002-08-19 | 2005-03-22 | 삼성전자주식회사 | 전자렌지 |
| MXPA05002617A (es) | 2002-09-09 | 2005-09-08 | Warren Pharmaceuticals Inc | Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena. |
| CA2500715A1 (en) * | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Hla binding peptides and their uses |
| JP2004305006A (ja) * | 2003-04-01 | 2004-11-04 | Japan Science & Technology Agency | 人工調製肺サーファクタント |
| EP2289526B1 (en) * | 2003-04-25 | 2014-06-11 | The University of Pittsburgh | Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration. |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| CN1882355A (zh) | 2003-09-09 | 2006-12-20 | 沃伦药品公司 | 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 |
| EA010650B1 (ru) | 2003-09-29 | 2008-10-30 | Уоррен Фармасьютикалз, Инк. | Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек |
| US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| EP1888629B1 (en) | 2005-05-10 | 2013-04-24 | Neoloch Aps | Neuritogenic peptides |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| EP1888098A2 (en) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| CN101378772B (zh) * | 2005-08-05 | 2013-12-04 | 阿拉伊姆药品公司 | 组织保护性肽及其用途 |
| HUE026591T2 (hu) | 2007-11-29 | 2016-06-28 | Molecular Health Gmbh | Szövetvédõ eritropoietin receptor (nepor) és alkalmazási eljárásai |
| PL2245056T4 (pl) | 2008-01-22 | 2016-01-29 | Araim Pharmaceuticals Inc | Peptydy i analogi peptydowe chroniące tkanki do zapobiegania i leczenia chorób i schorzeń związanych z uszkodzeniem tkanek |
| EP2297182A4 (en) * | 2008-04-28 | 2012-08-15 | Harvard College | HIGHLY CHARGED PROTEINS USED FOR CELL PENETRATION |
| WO2011022056A2 (en) | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF |
-
2006
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es active Active
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/en not_active Ceased
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Ceased
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Ceased
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko not_active Ceased
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/en active Active
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 SI SI200632230T patent/SI2594279T1/en unknown
- 2006-08-07 CA CA2982909A patent/CA2982909A1/en not_active Abandoned
- 2006-08-07 EP EP06801051A patent/EP1924276A4/en not_active Withdrawn
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Ceased
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/en not_active Withdrawn
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko not_active Expired - Fee Related
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Ceased
- 2006-08-07 CA CA2618396A patent/CA2618396C/en not_active Expired - Fee Related
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/en active Active
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 SI SI200632233T patent/SI2540309T1/en unknown
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko not_active Expired - Fee Related
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es active Active
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/en active Active
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es active Active
- 2006-08-07 CA CA3079319A patent/CA3079319A1/en not_active Abandoned
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
-
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
-
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
-
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0614529A8 (pt) | polipeptídeo isolado, composição farmacêutica, método para proteger, manter ou melhorar a viabilidade de uma célula, tecido ou órgão responsivos isolados do corpo do mamífero, uso de um polipeptídeo isolado, método para facilitar a transcitose de uma molécula, ácido nucleico isolado, vetor, célula hospedeira, e, método para produzir recombinantemente o polipeptídeo isolado | |
| Bartegi et al. | Characterization of the carboxyl-terminal 10-kDa cyanogen bromide fragment of caldesmon as an actin-calmodulin-binding region. | |
| Kalyukina et al. | TAS‐120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure | |
| Wilson et al. | Mapping the position of translational elongation factor EF-G in the ribosome by directed hydroxyl radical probing | |
| Dekan et al. | Total synthesis of human hepcidin through regioselective disulfide‐bond formation by using the safety‐catch cysteine protecting group 4, 4′‐dimethylsulfinylbenzhydryl | |
| BRPI0816405B8 (pt) | complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação | |
| US20130053544A1 (en) | Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds | |
| BR0015137A (pt) | Peptìdeos antigênicos de neisseria | |
| BR9914708A (pt) | Composição de matéria, dna, vetor de expressão, célula hospedeira, e, processo para preparar um composto farmacologicamente ativo | |
| Karkhanis et al. | Allergic encephalomyelitis. Isolation of an encephalitogenic peptide active in the monkey. | |
| DK1641818T3 (da) | Polypeptider der har bindingsaffinitet for HER2 | |
| ATE443161T1 (de) | Mittel und verfahren für den nachweis von methylierter dna | |
| Mezgueldi et al. | Characterization of the Regulatory Domain of Gizzard Calponin: INTERACTIONS OF THE 145-163 REGION WITH F-ACTIN, CALCIUM-BINDING PROTEINS, AND TROPOMYOSIN | |
| Beck et al. | A single amino acid can switch the oligomerization state of the α‐helical coiled‐coil domain of cartilage matrix protein | |
| BR112022007619A2 (pt) | Molécula de ligação específica, molécula de fusão de molécula de ligação específica anti-cd3, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou geneticamente modificada, composição farmacêutica, método para tratar um sujeito humano com câncer ou tumor e método para produzir uma molécula de ligação específica | |
| BRPI0412607A (pt) | método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes | |
| Hegyi et al. | Intrastrand cross-linked actin between Gln-41 and Cys-374. I. Mapping of sites cross-linked in F-actin by N-(4-azido-2-nitrophenyl) putrescine | |
| Oleinikov et al. | Structural and functional domains of Escherichia coli ribosomal protein L7/L12. The hinge region is required for activity. | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| EP1419267A2 (en) | Methods and means of histone methylation | |
| Spolaore et al. | Site-specific derivatization of avidin using microbial transglutaminase | |
| Takagi et al. | Amino acid sequence of vitamin D‐dependent calcium‐binding protein from bovine cerebellum | |
| Köpke et al. | Structure function relationships in the ribosomal stalk proteins of archaebacteria. | |
| BRPI0407399A (pt) | molécula, vetor recombinante, polipeptìdeo purificado, anticorpos purificados, célula hospedeira, métodos para produzir um polipeptìdeo, para detectar uma racemase codificada por um suqüência de nucleotìdeos, para tratar uma molécula, para detectar um d-aminoácido e para detectar atividade racemase em um meio de reação, complexo imunológico, kit, composição imunizante, e, plataforma tecnológica e todos os reagentes e dispositivos | |
| BR9911223A (pt) | Proteìnas de ligação à angiostatina, peptìdeos de ligação a um fragmento n-terminal do plasminogênio, ácidos nucleicos codificantes das referidas proteìnas e peptìdeos, vetores compreendendo o referidos ácidos nucleicos, células recombinantes contendo os referidos vetores, anticorpos que se ligam às referidas proteìnas ou peptìdeos, células recombinantes que expressam os referidos anticorpos , método de varredura de compostos capazes de interagir com as referidas proteìnas, compostos identificados pelo referido método, uso das referidas proteìnas, peptìdeos ou compostos na preparação de medicamentos para o tratamento de doença ou desordem relacionada à angiogênese e preparação farmacêutica contendo as referidas proteìnas, peptìdeos ou compostos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA NO 020080117377/RJ DE 05/09/2008, POR AUSENCIA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE O TITULAR DO PEDIDO JA E O INTERESSADO NA TRANSFERENCIA. |
|
| B150 | Others concerning applications: publication cancelled [chapter 15.30 patent gazette] |
Free format text: ANULADO O DESCONHECIMENTO DA PETICAO NO 020080117377/RJ DE 05/09/2008, PUBLICADO NA RPI 2145 DE 14/02/2012 POR TER SIDO INDEVIDO. |
|
| B25A | Requested transfer of rights approved |
Owner name: ARAIM PHARMACEUTICALS, INC. (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |